Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

NCT06306014 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT06306014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06306014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 7, 2024
Completion date
January 7, 2028
Enrollment
56 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

clostridioides difficile infection, recurrent infection